Nutriband Inc. (NTRB)
7.23
0.02 (0.28%)
At close: Feb 28, 2025, 3:59 PM
7.27
0.55%
After-hours: Feb 28, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 6.8 |
| Market Cap | 80.3M |
| Revenue (ttm) | 2.02M |
| Net Income (ttm) | -6.85M |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -10.18 |
| Forward PE | -14.07 |
| Analyst | Buy |
| Ask | 7.55 |
| Volume | 36,709 |
| Avg. Volume (20D) | 218,061 |
| Open | 7.08 |
| Previous Close | 7.21 |
| Day's Range | 6.89 - 7.25 |
| 52-Week Range | 2.22 - 11.78 |
| Beta | 0.46 |
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; e...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol NTRB
Website https://nutriband.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NTRB stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 79.81% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 weeks ago
+17.09%
Nutriband shares are trading higher after the comp...
Unlock content with
Pro Subscription
1 month ago
+40.88%
Nutriband shares are trading higher after Noble Capital Markets initiated coverage on the stock with an Outperform rating and a $13 price target.